MCID: LNG017
MIFTS: 43

Lung Giant Cell Carcinoma malady

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Giant Cell Carcinoma

Aliases & Descriptions for Lung Giant Cell Carcinoma:

Name: Lung Giant Cell Carcinoma 12 14
Carcinoma, Giant Cell 42 69
Giant Cell Carcinoma of Lung 69
Giant Cell Lung Carcinoma 12
Giant Cell Carcinoma 12
Carcinoma Giant Cell 52

Classifications:



External Ids:

Disease Ontology 12 DOID:5583
MeSH 42 D018286
NCIt 47 C3779 C4452
SNOMED-CT 64 254631008 42596004

Summaries for Lung Giant Cell Carcinoma

Disease Ontology : 12 A lung carcinoma that is located in large undifferentiated cells.

MalaCards based summary : Lung Giant Cell Carcinoma, also known as carcinoma, giant cell, is related to lysosomal storage disease and amyotrophic lateral sclerosis type 14, and has symptoms including coughing, dyspnea and fever. An important gene associated with Lung Giant Cell Carcinoma is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Miconazole and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include lung and large undifferentiated cells, and related phenotypes are growth/size/body region and mortality/aging

Wikipedia : 71 Giant-cell carcinoma of the lung (GCCL) is a rare histological form of large-cell lung carcinoma, a... more...

Related Diseases for Lung Giant Cell Carcinoma

Diseases related to Lung Giant Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Related Disease Score Top Affiliating Genes
1 lysosomal storage disease 10.2 MYC TIMP1
2 amyotrophic lateral sclerosis type 14 10.2 CDH1 CXCL8
3 hypersensitivity reaction type iii disease 10.2 CXCL8 MMP9
4 angiomyoma 10.2 MMP2 TIMP1
5 vallecula cancer 10.2 CDH1 NME1
6 glucose intolerance 10.1 CXCL8 TIMP1
7 embryonal testis carcinoma 10.1 CDH1 KRT18
8 speech and communication disorders 10.1 MMP2 TIMP1
9 facio skeletal genital syndrome rippberger type 10.1 MMP2 MMP9
10 acute tricyclic antidepressant poisoning 10.1 MMP2 MMP9
11 kleptomania 10.1 MMP2 MMP9
12 leukoencephalopathy palmoplantar keratoderma 10.1 MMP2 MMP9
13 thymus adenocarcinoma 10.1 MMP2 MMP9
14 ovarian wilms' cancer 10.1 CXCL8 KRT18 MYC
15 spinal meninges cancer 10.1 MMP2 MMP9
16 senile atrophy of choroid 10.1 MMP2 MMP9
17 omsk hemorrhagic fever 10.1 CXCL8 MMP9
18 tinea profunda 10.1 MMP2 MMP9
19 viral meningitis 10.1 MMP2 MMP9
20 gastric dilatation 10.1 CXCL8 MMP2
21 lymphocytic colitis 10.1 MMP2 MMP9
22 adenocarcinoma in situ 10.1 MMP2 MMP9
23 autoimmune polyendocrine syndrome type 1 10.1 CXCL8 MMP9 TIMP1
24 corneal staphyloma 10.0 MMP2 MMP9
25 chancroid 10.0 CXCL8 IL6R
26 linear porokeratosis 10.0 MMP2 MMP9
27 chordoid meningioma 10.0 CXCL8 MMP9 TIMP1
28 burns 10.0 CXCL8 MMP9 TIMP1
29 appendiceal l-cell glucagon-like peptide producing tumor 10.0 CXCL8 MMP2
30 esophageal neuroendocrine tumor 10.0 CDH1 MMP2 TIMP1
31 nervous system cancer 10.0 CXCL8 MMP9 TIMP1
32 retinal artery occlusion 10.0 MMP2 MMP9
33 intratubular embryonal carcinoma 10.0 CXCL8 MMP9 TIMP1
34 bulbomembranous urethral cancer 10.0 MMP2 MMP9
35 dental caries 10.0 CDH1 MMP2 NME1
36 nasal cavity disease 10.0 CDH1 MMP2 NME1
37 chondrodysplasia punctata, rhizomelic, type 1 10.0 CDH1 MMP9 TIMP1
38 vitreoretinopathy, neovascular inflammatory 10.0 CXCL8 IL6R
39 histiocytoma 10.0 CXCL8 MMP9
40 neonatal hypoxic and ischemic brain injury 10.0 CXCL8 MMP2 MMP9
41 trichomalacia 10.0 CXCL8 MMP2 MMP9
42 congenital hypomyelination neuropathy 10.0 MMP9 MYC TIMP1
43 onychocytic matricoma 10.0 MMP2 MMP9
44 appendix carcinoid tumor 10.0 MMP2 MMP9 TIMP1
45 schwannomatosis 10.0 MMP2 MMP9 TIMP1
46 striated muscle rhabdoid tumor 10.0 MMP2 MMP9 TIMP1
47 adenoid squamous cell carcinoma 10.0 MMP2 MMP9 TIMP1
48 retinal drusen 10.0 MMP2 MMP9 TIMP1
49 thanatophoric dysplasia, type ii 10.0 MMP2 MYC NME1
50 breast abscess 10.0 MMP2 MMP9 TIMP1

Graphical network of the top 20 diseases related to Lung Giant Cell Carcinoma:



Diseases related to Lung Giant Cell Carcinoma

Symptoms & Phenotypes for Lung Giant Cell Carcinoma

UMLS symptoms related to Lung Giant Cell Carcinoma:


coughing, dyspnea, fever, hemoptysis

MGI Mouse Phenotypes related to Lung Giant Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.76 CDH1 IL6R KRT18 MMP2 MMP9 MYC
2 mortality/aging MP:0010768 9.56 KRT18 MMP2 MMP9 MYC NME1 TIMP1
3 neoplasm MP:0002006 9.17 CDH1 IL6R MMP2 MMP9 MYC NME1

Drugs & Therapeutics for Lung Giant Cell Carcinoma

Drugs for Lung Giant Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
2
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177
3
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
4
Morphine Approved, Investigational Phase 3 57-27-2 5288826
5
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
8 Anti-Infective Agents Phase 2, Phase 3,Phase 1
9 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
10 Antifungal Agents Phase 2, Phase 3
11 Liver Extracts Phase 3,Phase 2,Phase 1
12 Antibiotics, Antitubercular Phase 2, Phase 3
13 pancreatic polypeptide Phase 3,Phase 1
14 Epoetin alfa Phase 3 113427-24-0
15 Analgesics Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Narcotics Phase 3
18 Analgesics, Opioid Phase 3
19 Anesthetics Phase 3
20 Anesthetics, General Phase 3
21 Anesthetics, Intravenous Phase 3
22 Peripheral Nervous System Agents Phase 3,Phase 1
23 Central Nervous System Depressants Phase 3
24 Cola Nutraceutical Phase 3,Phase 1
25
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
26
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
27
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
28
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
29
Tamoxifen Approved Phase 2 10540-29-1 2733526
30
nivolumab Approved Phase 2 946414-94-4
31
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
32
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
33
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
34
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
35
Mechlorethamine Approved Phase 1, Phase 2 51-75-2 4033
36
Dabrafenib Approved Phase 2 44462760 44516822
37
Doxil Approved June 1999 Phase 2 31703
38 Alkylating Agents Phase 1, Phase 2
39 Steroid Synthesis Inhibitors Phase 2
40 Hormone Antagonists Phase 2,Phase 1
41 Hormones Phase 2,Phase 1
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
43 Estrogen Antagonists Phase 2
44 Estrogens Phase 2
45 Aromatase Inhibitors Phase 2
46 Antineoplastic Agents, Alkylating Phase 1, Phase 2
47
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
48 Selective Estrogen Receptor Modulators Phase 2
49 Albumin-Bound Paclitaxel Phase 2,Phase 1
50 Topoisomerase Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 23)
id Name Status NCT ID Phase
1 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
4 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2
5 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
6 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
7 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2
8 TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00563784 Phase 2
9 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2
10 Phase II Pediatric Study With Dabrafenib in HGG Patients Not yet recruiting NCT02684058 Phase 2
11 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1
12 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
13 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
14 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
15 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1
16 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1
17 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1
18 A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors Active, not recruiting NCT01494688 Phase 1
19 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1
20 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1
21 Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma Unknown status NCT00568906
22 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733
23 Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer Terminated NCT02306135

Search NIH Clinical Center for Lung Giant Cell Carcinoma

Cochrane evidence based reviews: carcinoma, giant cell

Genetic Tests for Lung Giant Cell Carcinoma

Anatomical Context for Lung Giant Cell Carcinoma

MalaCards organs/tissues related to Lung Giant Cell Carcinoma:

39
Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Giant Cell Carcinoma:

18
Large Undifferentiated Cells

Publications for Lung Giant Cell Carcinoma

Articles related to Lung Giant Cell Carcinoma:

id Title Authors Year
1
[Study on differentially expressed molecules influencing the metastatic potential between highly and poorly metastatic human lung giant cell carcinoma]. ( 14690554 )
2003
2
Selective effect of O-alkyl lysophospholipids on the growth of a human lung giant cell carcinoma cell line. ( 8017834 )
1994
3
Coding region structure of interleukin-8 gene of human lung giant cell carcinoma LU65C cells that produce LUCT/interleukin-8: homogeneity in interleukin-8 genes. ( 2200751 )
1990
4
Purification and partial primary sequence of a chemotactic protein for polymorphonuclear leukocytes derived from human lung giant cell carcinoma LU65C cells. ( 2659722 )
1989

Variations for Lung Giant Cell Carcinoma

Cosmic variations for Lung Giant Cell Carcinoma:

9 (show top 50) (show all 80)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM905 RB1 lung,NS,carcinoma,giant cell carcinoma c.245C>A p.S82* 20
2 COSM516 KRAS lung,NS,carcinoma,giant cell carcinoma c.34G>T p.G12C 20
3 COSM6224 EGFR lung,NS,carcinoma,giant cell carcinoma c.2573T>G p.L858R 20
4 COSM95548 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 15
5 COSM95544 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 15
6 COSM95531 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 15
7 COSM95521 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 15
8 COSM95485 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 15
9 COSM95476 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 15
10 COSM96265 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64I 15
11 COSM94159 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 15
12 COSM94158 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 15
13 COSM95420 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 15
14 COSM95390 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 15
15 COSM43750 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.811G>T p.E271* 15
16 COSM43753 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.560-1G>A p.? 15
17 COSM10742 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 15
18 COSM10768 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 15
19 COSM95367 TLR5 lung,NS,carcinoma,undifferentiated carcinoma c.1A>G p.M1V 15
20 COSM95359 TLR4 lung,NS,carcinoma,undifferentiated carcinoma c.337C>A p.P113T 15
21 COSM95356 TLR2 lung,NS,carcinoma,undifferentiated carcinoma c.1169A>G p.Q390R 15
22 COSM95347 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.1087C>T p.P363S 15
23 COSM95342 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.5624C>T p.S1875L 15
24 COSM95340 TLE4 lung,NS,carcinoma,undifferentiated carcinoma c.859A>C p.K287Q 15
25 COSM95334 TIAM1 lung,NS,carcinoma,undifferentiated carcinoma c.3718G>C p.E1240Q 15
26 COSM95292 STK38 lung,NS,carcinoma,undifferentiated carcinoma c.407C>G p.A136G 15
27 COSM95282 STAT1 lung,NS,carcinoma,undifferentiated carcinoma c.2042A>T p.Y681F 15
28 COSM95276 SPRY2 lung,NS,carcinoma,undifferentiated carcinoma c.652T>C p.C218R 15
29 COSM95270 SPOP lung,NS,carcinoma,undifferentiated carcinoma c.570A>C p.L190F 15
30 COSM94327 RNF145 lung,NS,carcinoma,undifferentiated carcinoma c.647G>A p.G216E 15
31 COSM95658 RIN1 lung,NS,carcinoma,undifferentiated carcinoma c.1210C>T p.Q404* 15
32 COSM95187 RICTOR lung,NS,carcinoma,undifferentiated carcinoma c.1711C>A p.H571N 15
33 COSM96136 PLCG1 lung,NS,carcinoma,undifferentiated carcinoma c.3366C>T p.D1122D 15
34 COSM95013 PKHD1 lung,NS,carcinoma,undifferentiated carcinoma c.2753C>A p.P918Q 15
35 COSM94967 PIK3C2A lung,NS,carcinoma,undifferentiated carcinoma c.3240A>T p.E1080D 15
36 COSM94958 PDIA4 lung,NS,carcinoma,undifferentiated carcinoma c.1735G>T p.V579F 15
37 COSM96110 PAX6 lung,NS,carcinoma,undifferentiated carcinoma c.372G>T p.G124G 15
38 COSM94918 PARP1 lung,NS,carcinoma,undifferentiated carcinoma c.790C>G p.L264V 15
39 COSM94897 P2RY1 lung,NS,carcinoma,undifferentiated carcinoma c.238A>G p.M80V 15
40 COSM94878 NTSR1 lung,NS,carcinoma,undifferentiated carcinoma c.808G>T p.A270S 15
41 COSM94867 NRG3 lung,NS,carcinoma,undifferentiated carcinoma c.490G>T p.A164S 15
42 COSM94848 NOTCH2 lung,NS,carcinoma,undifferentiated carcinoma c.5637G>A p.M1879I 15
43 COSM95032 MED1 lung,NS,carcinoma,undifferentiated carcinoma c.2444A>G p.H815R 15
44 COSM94685 MC5R lung,NS,carcinoma,undifferentiated carcinoma c.458T>C p.I153T 15
45 COSM94681 MAX lung,NS,carcinoma,undifferentiated carcinoma c.368A>G p.Y123C 15
46 COSM94657 MAML1 lung,NS,carcinoma,undifferentiated carcinoma c.2605C>A p.Q869K 15
47 COSM94614 LMTK2 lung,NS,carcinoma,undifferentiated carcinoma c.2931C>A p.S977R 15
48 COSM95625 LHCGR lung,NS,carcinoma,undifferentiated carcinoma c.1660C>T p.R554* 15
49 COSM520 KRAS lung,NS,carcinoma,undifferentiated carcinoma c.35G>T p.G12V 15
50 COSM95622 KIF27 lung,NS,carcinoma,undifferentiated carcinoma c.620C>G p.S207* 15

Expression for Lung Giant Cell Carcinoma

Search GEO for disease gene expression data for Lung Giant Cell Carcinoma.

Pathways for Lung Giant Cell Carcinoma

Pathways related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 36)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 CDH1 CXCL8 IL6R MMP2 MMP9 MYC
2
Show member pathways
13.1 CXCL8 IL6R MMP2 MMP9 MYC TIMP1
3
Show member pathways
12.78 CDH1 IL6R MMP2 MMP9 MYC
4
Show member pathways
12.55 CDH1 MMP2 MMP9 TIMP1
5 12.4 CDH1 CXCL8 MMP2 MMP9 MYC
6
Show member pathways
12.37 CDH1 MMP2 MMP9 MYC
7
Show member pathways
12.15 CXCL8 IL6R MMP9
8 12.11 MMP2 MMP9 MYC
9 12.04 CXCL8 MMP9 MYC
10 11.87 CDH1 IL6R MMP2 MMP9 MYC
11 11.85 CXCL8 MMP9 MYC
12 11.8 CDH1 MMP2 MMP9
13
Show member pathways
11.75 MMP2 MMP9 TIMP1
14 11.67 MMP2 MMP9 TIMP1
15
Show member pathways
11.66 IL6R MYC TIMP1
16 11.62 MMP9 MYC NME1
17 11.48 CXCL8 MMP2 MMP9
18 11.47 CXCL8 MMP2 MMP9 TIMP1
19
Show member pathways
11.45 CXCL8 MMP2 MMP9
20 11.45 CDH1 CXCL8 MMP2 MMP9 MYC
21 11.41 CXCL8 MMP2 MMP9 TIMP1
22 11.34 CDH1 MMP9
23 11.34 CXCL8 IL6R MYC
24
Show member pathways
11.32 MMP2 MMP9
25 11.31 CDH1 NME1
26 11.22 MMP2 MYC
27 11.22 CDH1 CXCL8 MMP2 MMP9 MYC
28 11.19 MMP2 MMP9
29 11.17 CDH1 NME1
30 11.16 CXCL8 MMP2
31 11.16 CXCL8 IL6R MMP2 MMP9 MYC TIMP1
32 11.14 CXCL8 MMP2 MMP9
33 11.1 CDH1 MYC
34 11.04 MMP2 MMP9
35 11.03 MMP2 MMP9
36 11.01 MMP9 TIMP1

GO Terms for Lung Giant Cell Carcinoma

Cellular components related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.1 CDH1 CXCL8 IL6R MMP2 MMP9 TIMP1

Biological processes related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.56 KRT18 MMP9 MYC TIMP1
2 embryo implantation GO:0007566 9.43 MMP2 MMP9
3 extrinsic apoptotic signaling pathway GO:0097191 9.4 IL6R KRT18
4 cellular response to fibroblast growth factor stimulus GO:0044344 9.37 CXCL8 MYC
5 endodermal cell differentiation GO:0035987 9.32 MMP2 MMP9
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.16 MMP2 MMP9
7 positive regulation of DNA binding GO:0043388 9.13 MMP9 MYC NME1
8 extracellular matrix disassembly GO:0022617 8.92 CDH1 MMP2 MMP9 TIMP1

Sources for Lung Giant Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....